Display options
Cite
Oyama K, Koda M, Sugihara T, et al. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol. 2015;3(3):655-662doi: 10.3892/mco.2015.523.
Oyama, K., Koda, M., Sugihara, T., Kishina, M., Miyoshi, K., Okamoto, T., Hodotsuka, M., Fujise, Y., Matono, T., Tokunaga, S., Okamoto, K., Hosho, K., Okano, J., & Murawaki, Y. (2015). Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Molecular and clinical oncology, 3(3), 655-662. https://doi.org/10.3892/mco.2015.523
Oyama, Kenji, et al. "Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma." Molecular and clinical oncology vol. 3,3 (2015): 655-662. doi: https://doi.org/10.3892/mco.2015.523
Oyama K, Koda M, Sugihara T, Kishina M, Miyoshi K, Okamoto T, Hodotsuka M, Fujise Y, Matono T, Tokunaga S, Okamoto K, Hosho K, Okano J, Murawaki Y. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol. 2015 May;3(3):655-662. doi: 10.3892/mco.2015.523. Epub 2015 Mar 03. PMID: 26137283; PMCID: PMC4471610.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2015 May;3(3):655-662. doi: 10.3892/mco.2015.523. Epub 2015 Mar 03.

Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma.

Molecular and clinical oncology

Kenji Oyama, Masahiko Koda, Takaaki Sugihara, Manabu Kishina, Kenichi Miyoshi, Toshiaki Okamoto, Masanori Hodotsuka, Yuki Fujise, Tomomitsu Matono, Shiho Tokunaga, Kinya Okamoto, Keiko Hosho, Junichi Okano, Yoshikazu Murawaki

Affiliations

  1. Tottori University Hospital Cancer Center, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8504, Japan.
  2. Division of Medicine and Clinical Science, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8504, Japan.

PMID: 26137283 PMCID: PMC4471610 DOI: 10.3892/mco.2015.523

Abstract

The aim of the present study was to predict the effects of transarterial infusion (TAI) chemotherapy based on early changes in α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) in patients with advanced hepatocellular carcinoma (HCC). Seventy-four patients who underwent TAI with cisplatin, 5-fluorouracil, mitomycin C and epirubicin for advanced HCC were enrolled. Antitumor responses were evaluated 6 months after TAI. Rapid and early responses were defined as the ratio of AFP or DCP after 1 week and 1 month compared to baseline. A total of 5, 10, 17 and 42 patients had complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), respectively. Early AFP response was significantly lower in the CR+PR compared to the SD+PD groups (P<0.01). The early DCP response was significantly lower in the CR+PR compared to the SD+PD. The sensitivity and specificity of rapid and early AFP responses in the CR+PR were 0.78 and 0.72, and 0.80 and 0.73, respectively, and those of rapid and early DCP responses were 0.67 and 0.65, and 0.77 and 0.71, respectively. The combination of AFP and DCP responses had higher specificity compared to AFP or DCP alone responses. Patients were divided into responder and non-responder groups to evaluate the prediction of survival outcome. Early responders of AFP, DCP and AFP+DCP, who were divided based on the cut-off values of CR+PR survived significantly longer than the non-responders (P<0.05). In conclusion, rapid or early responses of AFP and/or DCP levels 1 and 4 weeks after TAI chemotherapy helped to predict the treatment effects.

Keywords: des-γ-carboxy prothrombin; hepatocellular carcinoma; transarterial infusion chemotherapy; treatment response; α-fetoprotein

References

  1. Radiat Med. 1992 Sep-Oct;10(5):189-95 - PubMed
  2. World J Gastroenterol. 2005 Dec 21;11(47):7391-400 - PubMed
  3. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3869-73 - PubMed
  4. Aliment Pharmacol Ther. 2005 Aug 1;22(3):217-26 - PubMed
  5. J Clin Gastroenterol. 2009 May-Jun;43(5):489-95 - PubMed
  6. Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12 (4):465-73 - PubMed
  7. J Clin Oncol. 2009 Jan 20;27(3):446-52 - PubMed
  8. Hepatol Int. 2008 Mar;2(1):17-30 - PubMed
  9. Oncologist. 2009 Jul;14(7):717-25 - PubMed
  10. Drugs. 2009;69(2):223-40 - PubMed
  11. J Hepatol. 2008 Aug;49(2):223-32 - PubMed
  12. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  13. Cancer. 2010 Oct 1;116(19):4590-6 - PubMed
  14. Hepatol Res. 2010 Jul;40(7):686-92 - PubMed
  15. Hepatology. 1993 Oct;18(4):990-7 - PubMed
  16. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed
  17. J Gastroenterol. 2005 Jan;40(1):70-8 - PubMed
  18. J Gastroenterol Hepatol. 2012 Dec;27(12 ):1850-7 - PubMed
  19. J Clin Oncol. 2009 Dec 1;27(34):5734-42 - PubMed
  20. Br J Cancer. 2013 Oct 1;109(7):1904-7 - PubMed
  21. Oncology. 2007;72 Suppl 1:52-7 - PubMed
  22. J Gastroenterol Hepatol. 2012 Feb;27(2):313-22 - PubMed
  23. Ann Surg Oncol. 2009 Oct;16(10):2795-804 - PubMed
  24. Biologics. 2008 Dec;2(4):779-88 - PubMed
  25. Int J Cancer. 2010 Dec 15;127(12):2893-917 - PubMed
  26. Gastroenterology. 2012 May;142(6):1264-1273.e1 - PubMed
  27. Liver Int. 2011 Mar;31(3):369-76 - PubMed
  28. J Gastroenterol. 2010 Dec;45(12):1272-82 - PubMed

Publication Types